Evaluation of a novel, anti-herpes simplex virus compound, acyclovir elaidate (P-4010), in the female guinea pig model of genital herpes

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 1, 1999, Pages 53-61

  Jennings, R ^a   Smith, T L ^a   Myhren, F ^b   Phillips, J ^a   Sandvold, M L ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b STATOIL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR DERIVATIVE; ACICLOVIR ELAIDATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; DRUG SCREENING; FEMALE; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX VIRUS; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032911953     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.1.53     Document Type: Article

References (33)

1. Beauchamp, L. M., G. F. Orr, P. de Miranda, T. Burnette, H. J. Schaeffer, and T. A. Krenitsky. 1992. Amino acid ester pro-drugs of acyclovir. Antivir. Chem. Chemother. 3:157-164.
2. Bernstein, D. I., L. R. Stanberry, C. J. Harrison, J. C. Kappes, and M. G. Myers. 1986. Antibody responses, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir. J. Gen Virol. 67:1601-1612.
3. Bourne, N., F. J. Bravo, W. T. Ashton, L. C. Meurer, R. L. Tolman, J. D. Karkas, and L. R. Stanberry. 1992. Assessment of a selective inhibitor of herpes simplex virus thymidine kinase (L-653,180) as therapy for experimental recurrent genital herpes. Antimicrob. Agents Chemother. 36:2020-2024.
4. Boyd, M. R., T. H. Bacon, D. Sutton, and M. Cole. 1987. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob. Agents Chemother. 31:1238-1242.
5. Bravo, F. J., L. R. Stanberry, A. B. Kier, P. E. Vogt, and E. R. Kern. 1993. Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea-pigs. Antivir. Res. 21:59-72.
6. Cassady, K. A., and R. J. Whitley. 1997. New therapeutic approaches to the alpha-herpesvirus infections. J. Antimicrob. Chemother. 39:119-128.
7. Clements, W. L., M. E. Armstrong, R. D. Keys, and M. A. Liu. 1997. The prophylactic effect of immunisation with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea-pigs. Vaccine 15:857-860.
8. de Miranda, P., and S. S. Good. 1992. Species differences in the metabolism and disposition of antiviral nucleoside analogues: 1. Acyclovir. Antivir. Chem. Chemother. 3:1-8.
9. Ertl, P., W. Snowden, D. Lowe, W. Miller, P. Collins, and E. Littler. 1995. A comparative study of the in vitro and in vivo antiviral activities of acyclovir and penciclovir. Antivir. Chem. Chemother. 6:89-97.
10. Erturk, M., R. J. Phillpotts, M. J. Welch, and R. Jennings. 1991. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection. Vaccine 9:728-734.
11. Goldthorpe, S. E., M. R. Boyd, and H. J. Field. 1992. Effects of penciclovir and famciclovir in a murine model of encephalitis induced by intranasal inoculation of herpes simplex virus type 1. Antivir. Chem. Chemother. 3:37-47.
12. Kern, E. R. 1982. Acyclovir treatment of experimental genital herpes simplex virus infections. Am. J. Med. 73:100-107.
13. Krenitsky, T. A., W. W. Hall, P. de Miranda, L. M. Beauchamp, H. J. Schaeffer, and P. D. Whiteman. 1984. 6-Deoxyacyclovir: a xanthine oxidase-activated pro-drug of acyclovir. Proc. Natl. Acad. Sci. USA 81:3209-3213.
14. Landry, M. L., H. L. Lucia, G. D. Hsuing, A. D. Provonost, P. R. Dann, M. J. August, and D. R. Mayo. 1982. Effect of acyclovir on genital infections with herpes simplex virus types 1 and 2 in the guinea-pig. Am. J. Med. 73:143-150.
15. Mayo, D. R., H. L. Lucia, and G. D. Hsuing. 1983. Effect of phosphonoformate on symptomatic genital herpes simplex virus type 2 infection of guinea-pigs. Intervirology 19:26-32.
16. McGrath, B. J., and C. L. Newman. 1994. Genital herpes simplex infections in patients with the acquired immunodeficiency syndrome. Pharmacotherapy 14:529-542.
17. McLean, C. S., M. Erturk, R. Jennings, D. Ni Challanain, A. C. Minson, I. Duncan, M. E. G. Bournsell, and S. C. Inglis. 1994. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J. Infect. Dis. 170:1100-1109.
18. McLean, C. S., D. Ni Challanain, I. Duncan, M. E. G. Bournsell, R. Jennings, and S. C. Inglis. 1996. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine. Vaccine 14:987-992.
19. Nakao, M., M. Hazama, A. Mayumi-Aono, S. Hinuma, and Y. Fujisawa. 1994. Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein. J. Infect. Dis. 169:787-791.
20. Phillpotts, R. J., M. J. Welch, P. H. Ridgeway, A. C. Walkland, and J. Melling. 1988. A test for the relative potency of herpes simplex virus vaccines based upon the female guinea-pig model of HSV-2 genital infection. J. Biol. Stand. 16:109-118.
21. Provonost, A. D., H. L. Lucia, P. R. Dann, and G. D. Hsuing. 1982. Effect of acyclovir on genital herpes in guinea-pigs. J. Infect. Dis. 145:904-908.
22. Purifoy, D. M., L. M. Beauchamp, P. de Miranda, P. Ertl, S. Lacey, G. Roberts, S. G. Rahim, G. Darby, T. A. Krenitsky, and K. L. Powell. 1993. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J. Med. Virol. Suppl. 1:139-145.
23. Rawls, W. E., K. Iwamoto, E. Adam, and J. C. Melnick. 1970. Measurement of antibodies to herpesvirus type 1 and 2 in human sera. J. Immunol. 104: 599-606.
24. Richards, D. M., A. A. Carmine, R. N. Brogden, R. C. Heel, T. M. Speight, and G. S. Avery. 1983. Acyclovir: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 26:378-438.
25. Scriba, M. 1975. Herpes simplex virus infection in guinea-pigs: an animal model for studying latent and recurrent herpes simplex virus infection. Infect. Immun. 12:162-165.
26. Stanberry, L. R., D. I. Bernstein, R. L. Burke, C. Pachl, and M. G. Myers. 1978. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J. Infect. Dis. 155:914-920.
27. Stanberry, L. R., E. R. Kern, J. T. Richards, T. M. Abbott, and J. C. Overall. 1982. Genital herpes in guinea-pigs: pathogenesis of the primary infection and description of recurrent disease. J. Infect. Dis. 146:397-404.
28. Sutton, D., and E. R. Kern. 1993. Activity of famciclovir and penciclovir in HSV-infected animals; a review. Antivir. Chem. Chemother. 4(Suppl. 1):37-46.
29. Thackray, A. M., and H. J. Field. 1996. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J. Infect. Dis. 173:291-299.
30. Thornton, B., A. Baskerville, N. E. Bailey, J. M. Melling, and P. Hambleton. 1984. Herpes simplex virus genital infection of the female guinea-pig as a model for evaluation of an experimental vaccine. Vaccine 2:141-148.
31. Vere Hodge, R. A., and Y.-C. Cheng. 1993. The mode of action of penciclovir. Antivir. Chem. Chemother. 4(Suppl. 1):13-24.
32. Vere Hodge, R. A., D. Sutton, M. R. Boyd, M. R. Harnden, and R. L. Jarvest. 1989. Selection of an oral prodrug (BRL 42810; famciclovir) for the anti-herpesvirus agent (BRL 39123) [9-(4-hydroxy-3-hydromethylbut-1-yl)guanine; penciclovir]. Antimicrob. Agents Chemother. 33:1765-1773.
33. Wald, A., J. Zeh, G. Barnum, L. G. Davis, and L. Corey. 1994. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann. Intern. Med. 124:8-15.